Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 3 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.

Tenapanor proven safe, effective in treatment of IBS with constipation

16 Feb 2020

Treatment with tenapanor 50 mg twice daily (bid) results in improvement of constipation-predominant irritable bowel syndrome (IBS-C) symptoms and is generally well tolerated, a phase III study has shown.

A total of 629 patients with IBS-C were randomized to receive tenapanor 50 mg bid or placebo bid for 12 weeks, followed by a 4-week randomized withdrawal period. Of these, 606 (96.3 percent; mean age, 45 years; 81.4 percent women) were included in the intention-to-treat analysis set (tenapanor: n=307; placebo: n=299) and 533 (84.7 percent) completed the 12-week treatment period.

Significantly more patients treated with tenapanor vs placebo met the primary endpoint of a reduction in average weekly worst abdominal pain of ≥30.0 percent and an increase of ≥1 complete spontaneous bowel movement from baseline, both in the same week, for ≥6 weeks of the 12-week treatment period (27.0 percent vs 18.7 percent; p=0.020).

Tenapanor therapy also led to improvements in abdominal symptoms and global symptoms of IBS compared with placebo (p<0.05).

The most frequently reported adverse event was diarrhoea, which resulted in treatment cessation in 6.5 percent of patients receiving tenapanor and 0.7 percent of those treated with placebo during the 12-week treatment period.

In a previous study, tenapanor 50 mg bid was found to significantly increase stool frequency, as well as reduce abdominal symptoms in patients with IBS-C. [Am J Gastroenterol 2017;112:763-774]

 “Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 3 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.